0 0

Cited 0 times in

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

Authors
 Kyung Hwan Kim  ;  Joon Young Hur  ;  Jiae Koh  ;  Jinhyun Cho  ;  Bo Mi Ku  ;  June Young Koh  ;  Jong-Mu Sun  ;  Se-Hoon Lee  ;  Jin Seok Ahn  ;  Keunchil Park  ;  Myung-Ju Ahn  ;  Eui-Cheol Shin 
Citation
 IMMUNE NETWORK, Vol.20(6) : e48, 2020-12 
Journal Title
 IMMUNE NETWORK 
ISSN
 1598-2629 
Issue Date
2020-12
Keywords
CD39 ; Hyperprogressive disease ; Lung cancer ; PD-1-PD-L1 blockade ; Peripheral blood human mononuclear cells ; T cell
Abstract
Hyperprogressive disease (HPD) is a distinct pattern of progression characterized by acceleration of tumor growth after treatment with anti-PD-1/PD-L1 Abs. However, the immunological characteristics have not been fully elucidated in patients with HPD. We prospectively recruited patients with metastatic non-small cell lung cancer treated with anti-PD-1/PD-L1 Abs between April 2015 and April 2018, and collected peripheral blood before treatment and 7-days post-treatment. HPD was defined as ≥2-fold increase in both tumor growth kinetics and tumor growth rate between pre-treatment and post-treatment. Peripheral blood mononuclear cells were analyzed by multi-color flow cytometry to phenotype the immune cells. Of 115 patients, 19 (16.5%) developed HPD, 52 experienced durable clinical benefit (DCB; partial response or stable disease ≥6 months), and 44 experienced non-hyperprogressive progression (NHPD). Patients with HPD had significantly lower progression-free survival (p<0.001) and overall survival (p<0.001). When peripheral blood immune cells were examined, the pre-treatment frequency of CD39+ cells among CD8+ T cells was significantly higher in patients with HPD compared to those with NHPD, although it showed borderline significance to predict HPD. Other parameters regarding regulatory T cells or myeloid derived suppressor cells did not significantly differ among patient groups. Our findings suggest high pre-treatment frequency of CD39+CD8+ T cells might be a characteristic of HPD. Further investigations in a larger cohort are needed to confirm our results and better delineate the immune landscape of HPD.
Files in This Item:
T202006938.pdf Download
DOI
10.4110/in.2020.20.e48
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
Yonsei Authors
Kim, Kyung Hwan(김경환)
Shin, Ui Cheol(신의철)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/182808
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links